X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
KVK-Tech will be providing formulation and Chemistry, Manufacturing & Controls for Sen-Jam's first injectable anti-inflammatory therapeutic, SJP-100, which reduces the rate at which inflammatory proteins are released into the body from the immune system.
Lead Product(s): SJP-100
Therapeutic Area: Infections and Infectious Diseases Product Name: SJP-100
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: KVK-Tech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 10, 2024
Details:
SJP-002C (ketotifen) world most potent, orally available anti-inflammatory a person could obtain for a mild to moderate coronavirus infection, Sen-Jam's investigational therapeutic for treatment of COVID-19, SJP-002C is now actively enrolling patients for their clinical trial.
Lead Product(s): Ketotifen Fumarate,Indomethacin
Therapeutic Area: Infections and Infectious Diseases Product Name: SJP-002C
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: KVK-TECH, INC.
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2022
Details:
KVK will have exclusive manufacturing and supply rights for the product SJP-002C (Ketotifen) in the US. Sen-Jam will utilize the finished formulation and CMC report to enter licensing deals with contracting manufacturing companies (CMOs) globally.
Lead Product(s): Ketotifen Fumarate,Indomethacin
Therapeutic Area: Infections and Infectious Diseases Product Name: SJP-002C
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: KVK-TECH, INC.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 05, 2022
Details:
Sen-Jam Pharmaceutical has entered a development, manufacturing, distribution, and license agreement with KVK-Tech. This is a monumental milestone for the company and great news for their promising oral COVID-19 treatment, SJP-002C.
Lead Product(s): Ketotifen Fumarate,Indomethacin
Therapeutic Area: Infections and Infectious Diseases Product Name: SJP-002C
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: KVK-TECH, INC.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 22, 2022
Details:
Results from a recent pilot study showed that SJP-001, comprising a combination of naproxen and fexofenadine was significantly more effective in reducing alcohol hangover severity than placebo.
Lead Product(s): Naproxen,Fexofenadine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: SJP-001
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2022
Details:
The collaboration received official approval this past Friday from the Nepal Health Research Council and is now commencing Phase II Clinical Trials of SJP-002C, for a novel oral therapy to mitigate the symptoms and hospitalizations associated with COVID-19.
Lead Product(s): Ketotifen Fumarate,Indomethacin
Therapeutic Area: Infections and Infectious Diseases Product Name: SJP-002C
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Duke University School of Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 22, 2022
Details:
Sen-Jam’s investigational therapeutic for COVID-19, SJP-002C is scheduled to begin a clinical trial in December 2021 under a co-development agreement with Duke-NUS. SJP-002C is a potent anti inflammatory with antiviral capabilities and minimal side effects.
Lead Product(s): SJP-002C
Therapeutic Area: Infections and Infectious Diseases Product Name: SJP-002C
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2021
Details:
Sen-Jam has an open FDA Investigational New Drug (IND) application to begin a phase I clinical study for SPJ-001 and is in late-stage discussions with a US Licensee for distribution.
Lead Product(s): SPJ-001
Therapeutic Area: Psychiatry/Psychology Product Name: SPJ-001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
